Clinical Trial Update: [18F]ACI-15916 PET in α-synucleinopathies [EARLY_Phase 1]

View source ↗

Summary

AC Immune SA reports an early-phase 1 trial evaluating its PET radioligand [18F]ACI-15916 for imaging alpha-synuclein in Parkinson's disease, multiple system at…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia with Lewy Bodies
• Multiple System Atrophy
• Parkinson Disease

Drugs mentioned

• [18F]ACI-15916 (ACI-15916)

Snippet

Sponsor: AC Immune SA | Conditions: Parkinson's Disease (PD), Multiple System Atrophy (MSA) | EARLY_Phase 1 | Status: RECRUITING